GENinCode is a UK-incorporated company engaged in the risk assessment, prediction and prevention of cardiovascular disease (“CVD”), the leading cause of death worldwide accounting for approximately 18 million deaths annually.
The Company’s products and technology have been developed since 2008 and clinically tested on over 80,000 patients with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. The Company was incorporated in September 2018 following the acquisition of the assets and know-how of the Ferrer inCode and Gendiag.exe businesses, including the Company’s current product portfolio, Cardio inCode®, LiPID inCode®, SuDD inCode® and Thrombo inCode®, then a part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharma and healthcare company. Since 2007, these products have collectively had approximately €50 million invested in the research and development of these products.
Inaugural Annual Report
Having helped GENinCode with their admission document when they floated on AIM in July 2021, the Perivan shareholder communications team was delighted to be appointed to produce the inaugural Annual Report which was successfully completed and published on 23rd May 2022.
To view the full annual report, click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.